114 related articles for article (PubMed ID: 2984899)
1. Recombinant leukocyte A interferon as single agent therapy or in combination with cimetidine in patients with advanced colo-rectal carcinoma. A phase II investigation.
Flodgren P; Hugander A; Sjögren HO
Acta Radiol Oncol; 1985; 24(1):25-34. PubMed ID: 2984899
[TBL] [Abstract][Full Text] [Related]
2. Antibody delivery and effector cell activation in a phase II trial of recombinant gamma-interferon and the murine monoclonal antibody CO17-1A in advanced colorectal carcinoma.
Weiner LM; Moldofsky PJ; Gatenby RA; O'Dwyer J; O'Brien J; Litwin S; Comis RL
Cancer Res; 1988 May; 48(9):2568-73. PubMed ID: 3128400
[TBL] [Abstract][Full Text] [Related]
3. Therapy with high dose recombinant alpha 2 interferon (IFN-alpha 2) produces a depression in natural killer cell cytotoxicity.
Tank B; Marquet RL; Weimar W; Westbroek DL
Br J Cancer; 1984 Aug; 50(2):227-30. PubMed ID: 6466539
[No Abstract] [Full Text] [Related]
4. Influence in vitro on NK and K cell activities by cimetidine and indomethacin with and without simultaneous exposure to interferon.
Flodgren P; Sjögren HO
Cancer Immunol Immunother; 1985; 19(1):28-34. PubMed ID: 3844972
[TBL] [Abstract][Full Text] [Related]
5. Immune functions in melanoma patients during treatment with interferon [HuIFN-alpha (Le)] alone or in combination with cimetidine.
Flodgren P; Malmström P; Axelsson B; Boketoft A; Borgström S; Sjögren HO
Anticancer Res; 1985; 5(2):197-204. PubMed ID: 3994311
[TBL] [Abstract][Full Text] [Related]
6. Phase II trials of recombinant leukocyte A interferon in disseminated malignant melanoma: results in 96 patients.
Creagan ET; Ahmann DL; Frytak S; Long HJ; Chang MN; Itri LM
Cancer Treat Rep; 1986 May; 70(5):619-24. PubMed ID: 3518925
[TBL] [Abstract][Full Text] [Related]
7. Leukocyte adherence inhibition, natural killer cell activity, gamma-interferon production capacity and phytohemagglutinin response in patients treated with recombinant leukocyte A interferon.
Tank B; Bijma AM; Marquet RL; Eggermont AM; Weimar W; Jeekel J; Westbroek DL
Oncology; 1985; 42(3):157-63. PubMed ID: 3923413
[TBL] [Abstract][Full Text] [Related]
8. Clinical and immunological evaluation of 20 patients with advanced colorectal cancer treated with high dose recombinant leukocyte interferon-alpha A (rIFN alpha A).
Eggermont AM; Weimar W; Tank B; Dekkers-Bijma AM; Marquet RL; Lameris JS; Westbroek DL; Jeekel J
Cancer Immunol Immunother; 1986; 21(1):81-4. PubMed ID: 3632919
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of high-dose recombinant leukocyte alpha-2 interferon for metastatic colorectal cancer without previous systemic treatment.
Eggermont AM; Weimar W; Marquet RL; Laméris JD; Jeekel J
Cancer Treat Rep; 1985 Feb; 69(2):185-7. PubMed ID: 3882227
[TBL] [Abstract][Full Text] [Related]
10. Treatment of patients with disseminated colorectal cancer with recombinant human alpha 2-interferon. Studies on the immune system.
Einhorn S; Wasserman J; Lundell G; Blomgren H; Cedermark B; Jarstrand C; Petrini B; Strander H; Theve T; Ohman U
Int J Cancer; 1984 Feb; 33(2):251-6. PubMed ID: 6229496
[TBL] [Abstract][Full Text] [Related]
11. Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A.
Liljefors M; Nilsson B; Hjelm Skog AL; Ragnhammar P; Mellstedt H; Frödin JE
Int J Cancer; 2003 Jul; 105(5):717-23. PubMed ID: 12740924
[TBL] [Abstract][Full Text] [Related]
12. Treatment of metastatic colorectal carcinoma with a combination of fluorouracil and recombinant interferon alfa-2b: preliminary data of a phase II study.
Weh HJ; Platz D; Braumann D; Buggisch P; Schmiegel WH; Drescher S; Kleeberg UR; Müllerleile U; Crone-Münzebrock W; Hoffman R
Semin Oncol; 1992 Apr; 19(2 Suppl 3):180-4. PubMed ID: 1557644
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of recombinant beta interferon in advanced colorectal cancer.
Lillis PK; Brown TD; Beougher K; Koeller J; Marcus SG; Von Hoff DD
Cancer Treat Rep; 1987 Oct; 71(10):965-7. PubMed ID: 3308080
[TBL] [Abstract][Full Text] [Related]
14. High-dose human lymphoblastoid interferon in metastatic colorectal cancer: clinical results and modification of biological responses.
Krown SE; Mintzer D; Cunningham-Rundles S; Niedzwiecki D; Krim M; Einzig AI; Gabrilove JL; Shurgot B; Gessula J
Cancer Treat Rep; 1987 Jan; 71(1):39-45. PubMed ID: 3791267
[TBL] [Abstract][Full Text] [Related]
15. Role of recombinant interferon alpha 2 and cimetidine in patients with advanced malignant melanoma.
Mughal TI; Robinson WA; Thomas MR; Spiegel R
J Cancer Res Clin Oncol; 1988; 114(1):108-9. PubMed ID: 3350837
[TBL] [Abstract][Full Text] [Related]
16. Divergent dose-related effects of gamma-interferon therapy on in vitro antibody-dependent cellular and nonspecific cytotoxicity by human peripheral blood monocytes.
Weiner LM; Steplewski Z; Koprowski H; Litwin S; Comis RL
Cancer Res; 1988 Feb; 48(4):1042-6. PubMed ID: 3123051
[TBL] [Abstract][Full Text] [Related]
17. A Phase II trial of high-dose intravenous interferon alpha-2 in advanced colorectal cancer.
Silgals RM; Ahlgren JD; Neefe JR; Rothman J; Rudnick S; Galicky FP; Schein PS
Cancer; 1984 Nov; 54(10):2257-61. PubMed ID: 6488145
[TBL] [Abstract][Full Text] [Related]
18. Effect of recombinant alpha interferon on NK and ADCC function in lung cancer patients: results from a phase II trial.
Hokland P; Hokland M; Olesen BK; Ernst P
J Interferon Res; 1984; 4(4):561-9. PubMed ID: 6094685
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of alpha (human leukocyte) interferon administered daily in adenocarcinoma of the colon/rectum.
Figlin RA; Callaghan M; Sarna G
Cancer Treat Rep; 1983 May; 67(5):493-4. PubMed ID: 6850664
[TBL] [Abstract][Full Text] [Related]
20. High dose rDNA human alpha 2 interferon therapy in patients with advanced colorectal adenocarcinoma: a phase II study.
Lundell G; Blomgren H; Cedermark B; Silfverswärd C; Theve T; Ohman U
Radiother Oncol; 1984 Mar; 1(4):325-32. PubMed ID: 6505269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
